Chemical inhibitors of RBMS2 can exert their inhibitory effects through a variety of biochemical and cellular mechanisms. Staurosporine, a kinase inhibitor, can disrupt key signaling pathways that are essential for RBMS2's function in RNA binding and modulation. By inhibiting these kinases, staurosporine can alter the phosphorylation state of proteins that interact with RBMS2 or are involved in its regulation. LY294002 and rapamycin target the PI3K/AKT/mTOR pathway, which is integral to cellular growth and metabolism. LY294002 directly inhibits PI3K, which can attenuate AKT signaling and indirectly affect RBMS2's activity. Rapamycin, by inhibiting mTOR, can decrease the phosphorylation of downstream proteins that may interact with RBMS2, thereby inhibiting its function.
Spliceostatin A and pladienolide B specifically target the splicing machinery, which is closely related to the function of RBMS2 in RNA processing. By inhibiting the splicing of pre-mRNAs that RBMS2 binds, spliceostatin A can functionally inhibit RBMS2. Similarly, pladienolide B disrupts the spliceosome function, which can lead to a functional inhibition of RBMS2's RNA-binding activity. MEK inhibitors like U0126 and PD98059 can impair the ERK signaling pathway, which may regulate processes essential for RBMS2's activity; thus, inhibiting MEK can lead to an inhibition of RBMS2. Leflunomide, by inhibiting pyrimidine synthesis, can influence the availability of RNA substrates that RBMS2 would typically bind, thereby inhibiting its function. 5-Azacytidine, which incorporates into RNA, can interfere with RNA-protein interactions, directly inhibiting RBMS2's ability to bind its RNA targets. Triptolide disrupts transcriptional processes, which indirectly inhibits RBMS2 by reducing the RNA available for binding. Flavopiridol inhibits CDKs, affecting transcription regulation and cell cycle progression, which can inhibit RBMS2's role in RNA processing. Lastly, Actinomycin D intercalates into DNA, inhibiting transcription, thus reducing the RNA substrate pool essential for RBMS2's interaction and function.
SEE ALSO...
Items 1 to 10 of 12 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Staurosporine | 62996-74-1 | sc-3510 sc-3510A sc-3510B | 100 µg 1 mg 5 mg | $82.00 $150.00 $388.00 | 113 | |
Staurosporine is a potent inhibitor of protein kinases. Inhibition of these kinases can disrupt signaling pathways that RBMS2 may rely on for RNA binding and modulation. | ||||||
LY 294002 | 154447-36-6 | sc-201426 sc-201426A | 5 mg 25 mg | $121.00 $392.00 | 148 | |
LY294002 is a PI3K inhibitor. By inhibiting PI3K, it can attenuate downstream AKT signaling, which is potentially involved in pathways that regulate RBMS2 activity. | ||||||
Rapamycin | 53123-88-9 | sc-3504 sc-3504A sc-3504B | 1 mg 5 mg 25 mg | $62.00 $155.00 $320.00 | 233 | |
Rapamycin inhibits mTOR, which could reduce the phosphorylation states of proteins that interact with or are involved in the regulatory processes of RBMS2. | ||||||
Spliceostatin A | 391611-36-2 | sc-507481 | 1 mg | $1800.00 | ||
Spliceostatin A targets the splicing machinery and can inhibit the splicing of pre-mRNAs that RBMS2 is known to bind, thus functionally inhibiting RBMS2. | ||||||
Pladienolide B | 445493-23-2 | sc-391691 sc-391691B sc-391691A sc-391691C sc-391691D sc-391691E | 0.5 mg 10 mg 20 mg 50 mg 100 mg 5 mg | $290.00 $5572.00 $10815.00 $25000.00 $65000.00 $2781.00 | 63 | |
Pladienolide B disrupts spliceosome function. Given RBMS2's role in RNA binding and processing, this can lead to functional inhibition of RBMS2's RNA-binding activity. | ||||||
U-0126 | 109511-58-2 | sc-222395 sc-222395A | 1 mg 5 mg | $63.00 $241.00 | 136 | |
U0126 is a MEK inhibitor. Through inhibiting MEK, it can impair ERK pathway signaling, which may regulate processes that are essential for RBMS2's function. | ||||||
PD 98059 | 167869-21-8 | sc-3532 sc-3532A | 1 mg 5 mg | $39.00 $90.00 | 212 | |
PD98059 is another MEK inhibitor that can block ERK pathway signaling. This could inhibit downstream effects that indirectly regulate RBMS2 activity. | ||||||
Leflunomide | 75706-12-6 | sc-202209 sc-202209A | 10 mg 50 mg | $20.00 $81.00 | 5 | |
Leflunomide inhibits dihydroorotate dehydrogenase, which can lead to reduced pyrimidine synthesis, potentially impacting RBMS2's RNA-binding capacity. | ||||||
5-Azacytidine | 320-67-2 | sc-221003 | 500 mg | $280.00 | 4 | |
5-Azacytidine incorporates into RNA, which can interfere with RNA-protein interactions. This could inhibit RBMS2's ability to bind RNA. | ||||||
Triptolide | 38748-32-2 | sc-200122 sc-200122A | 1 mg 5 mg | $88.00 $200.00 | 13 | |
Triptolide disrupts transcriptional activity. Since RBMS2 is involved in RNA processing, hampering transcription can indirectly inhibit RBMS2's binding to RNA. | ||||||